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Abstract
Background: Diagnosing colorectal cancer (CRC) at an early stage improves survival. To what extent any delay affects 
outcome once patients are symptomatic is still unclear.
Our objectives were to evaluate the association between diagnostic delay and survival in symptomatic patients with
early stage CRC and late stage CRC.
Methods: Prospective population-based observational study evaluating daily clinical practice in Northern Holland. 
Diagnostic delay was determined through questionnaire-interviews. Dukes' stage was classified into two groups: early 
stage (Dukes A or B) and late stage (Dukes C or D) cancer. Patients were followed up for 3.5 years after diagnosis.
Results: In total, 272 patients were available for analysis. Early stage CRC was present in 136 patients while 136 patients 
had late stage CRC. The mean total diagnostic delay (SE) was 31 (1.5) weeks in all CRC patients. No significant difference 
was observed in the mean total diagnostic delay in early versus late stage CRC (p = 0.27).
In early stage CRC, no difference in survival was observed between patients with total diagnostic delay shorter and
longer than the median (Kaplan-Meier, log-rank p = 0.93).
In late stage CRC, patients with a diagnostic delay shorter than the median had a shorter survival than patients with a
diagnostic delay longer than the median (log-rank p = 0.01). In the multivariate Cox regression model with survival as
dependent variable and median delay, age, open access endoscopy, number and type of symptoms as independent
variables, the odd's ratio for survival in patients with long delay (>median) versus short delay (≤median) was 1.8 (95%
confidence interval (CI) 1.1 to 3.0; p = 0.01). Tumor-site was not associated with patient survival. When separating late
stage CRC in Dukes C and Dukes D tumors, a shorter delay was associated with a shorter survival in Dukes D tumors
only and not in Dukes C tumors.
Conclusion: In symptomatic CRC patients, a longer diagnostic and therapeutic delay in routine clinical practice was 
not associated with an adverse effect on survival. The time to CRC diagnosis and initiation of treatment did not differ 
between early stage and late stage colorectal cancer.
Background
Colorectal cancer (CRC) is the second leading cause of
cancer-related death in the Western world, with over
4500 deaths per year in The Netherlands and 500,000
deaths per year worldwide [1,2]. Despite advances in sur-
gery and systemic treatment, overall mortality rates have
remained relatively unchanged and long-term survival of
CRC is 55-58% [1,3,4]. Early diagnosis and prompt treat-
ment are believed to improve survival in patients with
CRC. In asymptomatic, average-risk populations, early
detection of (pre)malignant lesions by means of biennial
faecal occult blood testing (FOBT) has shown to reduce
CRC-related mortality [5]. In symptomatic patients, how-
ever, the yield of reducing time between onset of symp-
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toms and start of therapy in terms of improved survival is
controversial. Conflicting results have been published
considering the relationship between the duration of
CRC symptoms, tumor stage and survival [6-21]. In the
absence of a CRC screening program in the Netherlands,
symptoms that could indicate colorectal neoplasia, like
rectal bleeding, weight loss and altered bowel habits,
form the main indication for colonoscopy. However,
symptoms of CRC and its precursors can often be non-
specific and diffuse in character while distress of the gas-
trointestinal tract is common in the general population.
Therefore, early recognition of symptomatic CRC can be
a challenge for the patient as well as the physician, result-
ing in a delay in the start of appropriate treatment.
In the present study, we assessed the time between the
onset of symptoms and the date of definitive treatment in
all patients with symptomatic CRC in a prospective, pop-
ulation-based observational study, evaluating daily clini-
cal practice in the Northern Holland province. In
addition to information on delay and disease stage, we
analyzed survival of CRC patients after a follow up period
of 3.5 years. Our objectives were to evaluate whether a
difference would exist in diagnostic delay between symp-
tomatic patients with early stage CRC (Dukes stage A or
B) and late stage CRC (Dukes stages C or D), and to cor-
relate survival to duration of diagnostic delay and cancer
stage.
Methods
Study design
In this multi-centre, population-based, observational
study, daily endoscopic clinical practice was prospectively
evaluated during a three month period in 2005 in the
province Northern Holland [22]. All colonoscopies and
sigmoidoscopies performed in this time interval were
evaluated. All consecutive patients diagnosed with symp-
tomatic colorectal cancer were registered. The province
Northern Holland, serving a total community of
2,599,103 inhabitants in 2005 http://www.cbs.nl, counts
18 hospitals (2 academic hospitals and 16 general/teach-
ing hospitals). All 18 hospitals participated in this study.
The study protocol was approved by the central medical
ethics review board of the VU University Medical Centre
in Amsterdam. When information on diagnostic delay
was collected from patient questionnaire-interviews,
informed consent was obtained prior to data collection.
When information on delay was collected through inter-
viewing the general practitioner or assessing the medical
files, no informed consent was needed given the observa-
tional nature of this study as judged by the medical ethics
review board. Data on survival after 3.5 years of follow up
were obtained through the National Cancer Registry up
to the 1st of March 2009. For all CRC patients the follow-
ing items were scored: age, gender, family history of col-
orectal adenomas and/or cancer, personal history of
colorectal adenomas and/or cancer, symptoms attribut-
able to colorectal cancer, symptom duration, mode of
presentation, date of first general practitioners visit, date
of referral to hospital or endoscopy unit, date of diagno-
sis, date of onset of treatment or decision to abstain from
treatment, endoscopic findings, type of surgery/treat-
ment, surgical findings and histopathology data.
Study definitions
Diagnostic delay was defined as the time between the
onset of the first symptom(s) and the ultimate date of
treatment or decision to abstain from further treatment.
Total diagnostic delay was divided in patient's delay and
healthcare delay. Healthcare delay was subdivided in
referral delay, hospital diagnostic delay and staging/treat-
ment delay. The sum of patient's delay and healthcare
delay is the total diagnostic delay.
Patient's delay was defined as the time between first
onset of complaints and the initial presentation to a doc-
tor for these complaints. Healthcare delay was defined as
the time between first doctor's consultation for these
complaints and the ultimate date of treatment or until the
decision to abstain from further therapy. Referral delay
was defined as the time between first doctor's consulta-
tion for these complaints and the date of hospital referral.
Hospital diagnostic delay was defined as the time
between referral date and date of CRC diagnosis. Staging/
treatment delay was defined as the time between CRC
diagnosis and the ultimate date of treatment or until the
decision to abstain from further therapy.
Information on diagnostic delay was collected from
patient questionnaire-interviews. If the information
could not be collected from the patient, the general prac-
titioner was interviewed. If there were no data available
through the general practitioner, the patient's medical
files were assessed. If no accurate data on diagnostic delay
or tumor stage could be obtained, the patient was
excluded. All patient questionnaire-interviews and gen-
eral practitioner interviews were performed by the first
author. Analysis of the patient's medical files was per-
formed by the first author and his co-workers. Data on
referral delay, diagnostic delay and staging/treatment
delay were collected shortly after the CRC diagnosis
within a minimum of 6 months after initiation of treat-
ment.
When comparing diagnostic delay and survival in rectal
tumors versus colon tumors, synchronous colon and rec-
tal cancers were excluded. Tumors of the rectosigmoid
junction were counted as rectal tumors. Other exclusion
criteria were asymptomatic patients (i.e. patients with
family history of CRC or screening request) and asymp-
tomatic patients in a surveillance program due to an
increased risk for CRC (i.e. post-polypectomy surveil-Terhaar sive Droste et al. BMC Cancer 2010, 10:332
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lance, post-CRC surveillance, surveillance for hereditary
syndromes or surveillance for inflammatory bowel dis-
ease). We did include patients in a surveillance program
or with a family history of CRC when the colonoscopy
was performed for symptoms suggestive of CRC.
CRC was staged according to Dukes using information
from the surgical file and/or pathology report [23]. Early
stage CRC was defined as Dukes A or Dukes B tumors.
Late stage CRC was defined as Dukes C or Dukes D
tumors. All cause mortality was used in the survival anal-
yses.
Data analysis & statistics
We compared patient's delay, healthcare delay and total
diagnostic delay in patients with early stage CRC to
patients with late stage CRC. We dichotomized the vari-
able delay in total diagnostic delay shorter and longer
than the median delay of all patients. The survival of
patients with a total diagnostic delay shorter than median
was compared to the survival of patients with a total diag-
nostic delay longer than median by means of Kaplan-
Meier analysis. This was done for patients with early
stage CRC and late stage CRC separately. In addition to
the Kaplan-Meier analysis, we carried out a Cox regres-
sion analysis to study confounding and, where necessary,
corrected for confounding factors. Age, gender, tumor-
site, history of CRC or polyps, synchronous polyps, open-
a c c e s s  e n d o s c o p y ,  n u m b e r  a n d  t y p e  o f  s y m p t o m s  a n d
degree of tumor differentiation were considered as
potential clinical and pathological confounders. Kaplan-
Meier analysis and Cox regression were also used to study
the relation between survival time and tumor stage.
Patients lost to follow up were censored at the time last
known to be alive. All analyses were performed with SPSS
for Windows Version 15 (SPSS Inc., Chicago, Illinois,
USA).
Results
General results
In total, 376 CRCs were diagnosed after endoscopic eval-
uation of the large bowel during the three month study
period. All CRCs found during emergency abdominal
surgery without prior endoscopy (N = 38), were excluded
because of insufficient data on diagnostic delay and endo-
scopic findings. After exclusion of all patients in whom
insufficient clinical/histopathological data were collected,
the total number of patients available for analysis was 272
(Table 1). In 16% of patients (n = 44), information on
patient's delay was collected through patients question-
naire-interviews. In 24% of patients (n = 64), information
on patient's delay was collected through interviewing the
general practitioners and in 60% of patients (n = 164) this
information was collected by assessing the medical files.
Within these 272 patients, 136 patients were diagnosed
with early stage CRC (Dukes stage A or B) and 136
patients had late stage CRC (Dukes stages C or D). Table
2 shows the details on tumor-site and Dukes classifica-
tion. The overall mean age (±SD) was 69.5 ± 11 years,
range 40-94 years. No differences were observed in mean
age between early and late stage CRCs. Forty-nine per-
cent of patients was male (mean age for males 68.2 ± 11
years, mean age for females 70.8 ± 11 years). In 24
patients (9%), CRC was diagnosed in one of the two aca-
demic medical centres. The remaining 248 CRCs (91%)
were diagnosed in general/teaching hospitals. One hun-
dred patients (37%) had rectal cancer and 167 patients
(61%) had colon cancer. In 5 patients (2%) synchronous
colon and rectal cancer was found.
In 92% of patients, referral to the hospital followed ini-
tial presentation at the general practitioners office and in
8% of patients the initial presentation was on the emer-
gency room which warranted an endoscopic evaluation
of the colo-rectum.
In 57% of patients (n = 154), rectal bleeding was the pri-
mary indication for endoscopy. In 16% of patients (n = 44)
weight loss was the primary indication and a change in
bowel habits accounted for 13% (n = 34) of the procedure
indications. Twelve percent (n = 32) of patients presented
with an iron deficient anaemia and in 3% (n = 8) other
Table 1: Exclusion criteria and numbers of excluded 
patients
Family history of CRC (asymptomatic) 3
Post-CRC surveillance program (asymptomatic) 4
Post-polypectomy surveillance program (asymptomatic) 8
Surveillance for hereditary syndromes 3
Surveillance for inflammatory bowel disease 5
Lack of participation of general practitioner 10
Lack of data on patient delay 36
Lack of data on healthcare delay 15
Lack of data on tumor stage 20
Total 104
* In total 376 patients were diagnosed with CRC after endoscopic 
evaluation of the large bowel during the 3 months study period in 
this multi-centre, population-based study.
† Abbreviations: CRC = colorectal cancerTerhaar sive Droste et al. BMC Cancer 2010, 10:332
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indications like abdominal pain, tenesmus or bloatedness
were mentioned. Most patients (84%) presented with 2 or
more symptoms.
Diagnostic delay and tumor stage
The mean total diagnostic delay (SE) was 31.2 (1.5) weeks
in all CRC patients (range: within 1 week to >104 weeks).
A breakdown of total diagnostic delay into patient's delay
and healthcare delay is shown in Table 3, and of health-
care delay into referral delay, hospital diagnostic delay
and staging/treatment delay is shown in Table 4. The
mean and median diagnostic delay (SD and SE) for early
and late stage CRC separately are also shown in Table 3
and 4. Since the data on delay were skewed, we trans-
formed the delay data logarithmically and compared the
means using the independent-samples t-test. No signifi-
cant differences were observed in the mean total diagnos-
tic delay, the mean patient's delay and the mean
healthcare delay in early versus late stage CRC (p = 0.27, p
= 0.56 and p = 0.46, respectively tested on a logarithmic
scale). The absence of differences in diagnostic delay in
early and late stage disease is further illustrated by using
box plot graphics. Figures 1, 2 and 3 show box plot graph-
ics comparing the total diagnostic delay, patient's delay
and healthcare delay in early and late stage colorectal
cancer. Even though total healthcare delay did not show
significant differences in early versus late stage CRC,
specification of healthcare delay in referral delay, hospital
diagnostic delay and staging/treatment delay did show
that referral delay was significantly longer in late stage
CRC compared to early stage CRC (Table 4). Staging/
treatment delay, however, was significantly shorter in late
stage disease compared to early stage disease.
In colon and rectal cancer separately, the mean total
diagnostic delay (SE) was 28.2 (1.7) and 35.4 (2.8) weeks,
respectively (p = 0.02; tested on a logarithmic scale) (Fig-
ure 4). Patient's delay, but not healthcare delay, was the
contributing factor for the significantly longer diagnostic
delay in rectal cancers as compared to colon cancers (p =
0.04 versus p = 0.37; tested on a logarithmic scale). No
significant differences were observed in diagnostic delay
in early versus late stage CRC in either colon or rectal
cancers (p = 0.98 and p = 0.09, respectively).
There were no significant differences in diagnostic
delay between the academic centres and the general/
teaching hospitals (p = 0.44). Obviously, when a patient
presented in the hospital at the emergency room, a signif-
icantly shorter diagnostic delay was observed as com-
pared to referral via the general practitioner (p < 0.0001).
No significant differences in tumor stage were found
when a patient presented in the hospital via the emer-
gency room as compared to referral via the general prac-
titioner.
Table 2: Colorectal cancers (CRC) stratified by tumor-site and Dukes stage in 272 symptomatic patients diagnosed with 
CRC in a population-based study.
Dukes classification
Tumor-site Dukes A Dukes B Dukes C Dukes D Total
r e c t u m N 1 91 81 82 47 9
% 24% 23% 23% 30% 100%
rectosigmoid junction N 3 9 9 5 26
% 12% 35% 35% 19% 100%
sigmoid colon N 11 29 12 31 83
% 13% 35% 15% 37% 100%
descending colon N 2 3 1 4 10
% 20% 30% 10% 40% 100%
transverse colon N 2 7 4 1 14
% 14% 50% 29% 7% 100%
ascending colon N 1 16 3 6 26
% 4% 62% 12% 23% 100%
cecum N 4 12 7 11 34
% 12% 35% 21% 32% 100%
Total N 42 94 54 82 272
% 15% 35% 20% 30% 100%Terhaar sive Droste et al. BMC Cancer 2010, 10:332
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Table 3: Diagnostic delay in early versus late stage colorectal cancer (CRC) in 272 symptomatic patients diagnosed with 
CRC in a population-based study.
Early vs Late stage CRC patient's delay (weeks) healthcare delay (weeks) total diagnostic delay (weeks)
Early stage CRC Mean 12.6 17.1 29
(Dukes A&B, N = 136) Median 5.5 12 21.5
SD 19.8 15.7 22.9
SE 1.7 1.3 2
Late stage CRC Mean 15 19 33.4
(Dukes C&D, N = 136) Median 6 10 27
SD 23.3 21.4 26.9
SE 2 1.8 2.3
Total Mean 13.8 18 31.2
(N = 272) Median 6 12 23.5
SD 21.6 18.8 25
SE 1.3 1.1 1.5
Table 4: Specification of healthcare delay in early versus late stage colorectal cancer (CRC) in 272 symptomatic patients 
diagnosed with CRC in a population-based study.
Early vs Late stage 
CRC
healthcare delay 
(weeks)*
referral delay 
(weeks) †
hospital diagnostic 
delay (weeks) §
staging/treatment 
delay (weeks) ‡
Early stage CRC Mean 17.1 6.7 6.1 4.9
(Dukes A&B, N = 136) Median 12 1 3 4
SD 15.7 13.9 7.5 3.2
SE 1.3 1.2 0.6 0.3
Late stage CRC Mean 19 11 5.2 3.6
(Dukes C&D, N = 136) Median 10 2 2 3
SD 21.4 20.8 8.2 2.6
SE 1.8 1.8 0.7 0.2
Total Mean 18 8.8 5.7 4.2
(N = 272) Median 12 1 3 4
SD 18.8 17.8 7.9 2.9
SE 1.1 1.1 0.5 0.2
* No significant difference was observed in the mean healthcare delay in early versus late stage CRC
(p = 0.46; tested on a logarithmic scale using the independent-samples t-test).
† Mean referral delay was significantly longer in late stage CRC compared to early stage CRC
(p = 0.04; tested on a logarithmic scale using the independent-samples t-test).
§ No significant difference was observed in the mean hospital diagnostic delay in early versus late stage CRC
(p = 0.09; tested on a logarithmic scale using the independent-samples t-test).
‡ Mean staging/treatment delay was significantly shorter in late stage CRC compared to early stage CRC
(p < 0.0001; tested on a logarithmic scale using the independent-samples t-test).Terhaar sive Droste et al. BMC Cancer 2010, 10:332
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Figure 1 Mean total diagnostic delay in early and late stage colorectal cancer.
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Figure 2 Mean patient's delay in early and late stage colorectal cancer.
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Survival data
After 3.5 years of follow up, 41.5% of patients had died,
1.5% of patients were lost to follow up because of emigra-
tion and 57% of patients were still alive. Of the 113
patients that had died during the 3.5 years of follow up,
75% had late stage CRC and 25% had early stage CRC. In
early stage CRC, no difference in survival was observed
between patients with total diagnostic delay shorter ver-
sus longer than the median delay (Figure 5, log-rank p =
0.93). Correction for potential confounders in a Cox
regression analysis did not modify this observation. How-
ever, age was independently associated with patient sur-
vival. In late stage CRC, patients with a diagnostic delay
shorter than the median had a shorter survival than
patients with a diagnostic delay longer than the median
(Figure 6, log-rank p = 0.01). Age and open access endos-
copy were independently associated with patient survival
in late stage CRC. Also type and number of symptoms
were associated with patient survival (rectal bleeding and
patients presenting with >2 symptoms were associated
with poor prognosis). Tumor-site was not associated with
patient survival. In the multivariate Cox regression model
with survival as dependent variable and median delay,
age, open access endoscopy, number and type of symp-
toms as independent variables, the odd's ratio (OR) for
survival in patients with long delay (>median) versus
short delay (≤median) was 1.8 (95% confidence interval
(CI) 1.1 to 3.0; p = 0.01). When separating late stage CRC
in Dukes C and Dukes D tumors, a shorter delay was
associated with a shorter survival in Dukes D tumors only
and not in Dukes C tumors.
Discussion
In this prospective, population-based, observational
study, we included CRC patients which were diagnosed
endoscopically from all hospitals in the Northern Holland
province. All symptomatic patients were included, pro-
vided that all necessary data on diagnostic delay and
tumor stage could be obtained. To date, there is no CRC
screening program in place in The Netherlands and no
other institutions, like private practices or doctor's
offices, are performing endoscopies. Consequently, this
Figure 3 Mean healthcare delay in early and late stage colorectal cancer.
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study is a reliable representation of symptomatic CRC
patients with its diagnostic delay in Northern Holland.
Although referral delay was significantly longer in late
stage cancers compared to early stage cancers, we
observed no significant overall difference in diagnostic
delay between early and late stage cancers. In addition,
we found no relation between diagnostic delay and sur-
vival in early stage cancers. However, in late stage can-
cers, with Dukes D tumors as the culprit, a shorter delay
was associated with poor prognosis. These paradoxical
results on the relationship between duration of symp-
toms, tumor stage and survival, support the idea that the
biologic behavior of a given tumor is determined from the
very onset, and that this biologic pattern is an important,
if not the sole, determinant of the ultimate outcome. It
may be surmised that patients presenting after a shorter
duration of symptoms may be harboring more virulent
and biologically aggressive forms of cancers when com-
pared to patients with symptoms of longer duration.
These data may also suggest that, despite increasing
tumor cell population, colorectal cancers do not progress
in Dukes' stage during the symptomatic period. All col-
orectal cancers begin as adenomas, according to the
Muto and Morson adenoma-carcinoma sequence theory,
and it is believed that the progression of these adenomas
into cancer takes between 5 and 15 years [24,25]. The
symptomatic phase may be a very late event in the natural
history of the disease and 1-3 months make little differ-
ence in the overall history [26]. This lag time may explain
the lack of correlation between diagnostic delay and
prognosis. The actual relation between diagnostic delay,
tumor stage and survival is complex and might not be
elucidated by observational studies. Contradicting results
of a recent meta-analysis of observational studies on diag-
nostic delay and disease stage at diagnosis support this
notion [27]. Furthermore, most data regarding delay and
survival in CRC patients, suggest that there is no associa-
tion between diagnostic and therapeutic delay and sur-
vival [28].
Surprisingly, we found a distinct longer total diagnostic
delay in rectal cancer patients compared to colon cancer
patients. Although this finding is consistent with earlier
Figure 4 Mean total diagnostic delay in rectal and colon cancer.
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observations, it is somewhat paradoxical that rectal can-
cer, which has recognizable symptoms, has a longer delay
than colon cancer [29]. In the present study, healthcare
delay was the major contributor to the delay in diagnos-
ing both rectal and colon cancer. However, patient delay
was significantly longer in rectal cancer compared to
colon cancer despite the presence of a clear alarming
symptom (87% of patients with rectal cancer presented
with rectal bleeding, data not shown). It has been
described that alarming symptoms do not warrant a doc-
tor's visit and the reasons for this might be unawareness
of the importance of symptoms, embarrassment to con-
sult a doctor or fear of a possible cancer diagnosis [30]. In
spite of the longer delay in diagnosing rectal cancer, no
significant differences were observed in diagnostic delay
and tumor stage in both colon and rectal cancers.
The present study carries a number of limitations that
need to be considered for proper interpretation of the
results. The main limitation is the substantial number of
patients with inconclusive delay or histopathology data
with its risk of introducing selection bias. Although we
defined our study variables beforehand, there was no
interventional intent and therefore no standardized
reporting format. This means that evaluating daily clini-
cal practice surprisingly showed that not all data on delay
were recorded in the medical hospital files or in the gen-
eral practitioners files.
Figure 5 Survival analysis in early stage colorectal cancer. Survival in early stage CRC for diagnostic delay longer and shorter than the median 
delay of 23.5 weeks. On the Y-axis the proportion of patients surviving is plotted. On the X-axis the time is plotted in weeks. Log-rank p = 0.93 using 
Kaplan-Meier analysis. In the Cox regression model with survival as dependent variable and median delay, age, open access endoscopy, number and 
type of symptoms as independent variables, the odd's ratio for survival in patients with long delay (>median) versus short delay (≤median) was 1.1 
(95% confidence interval 0.5 to 2.6; p = 0.76). Blue line: delay < median delay. Green line: delay > median delay
Time in weeks
120.00 100.00 80.00 60.00 40.00 20.00 0.00
P
r
o
p
o
r
t
i
o
n
 
o
f
 
p
a
t
i
e
n
t
s
 
s
u
r
v
i
v
i
n
g
1.00
0.95
0.90
0.85
0.80Terhaar sive Droste et al. BMC Cancer 2010, 10:332
http://www.biomedcentral.com/1471-2407/10/332
Page 10 of 11
Furthermore, as in other studies that are based on
interview data, the inherent risk of recall bias exists.
Although the information on delay was collected shortly
after the diagnosis, the often non-specific symptoms of
colorectal cancer could not be scored at the time of onset
of complaints, increasing the risk of information bias. In
this study, we report on robust 3.5 year follow up data.
Unfortunately, only all cause mortality was available from
the National Cancer Registry, where cancer related mor-
tality data would have been more indicative. Finally, the
degree of tumor differentiation, a feature that may reflect
the pace of tumor growth, was unaccounted for in 60% of
the pathology reports [23]. Therefore, we were not able to
reliably correct for the potential confounding effect.
However, as the vast majority of CRCs are moderately dif-
ferentiated, this effect will probably be limited.
Conclusions
We found no significant difference in diagnostic delay
between early and late stage colorectal cancer in symp-
tomatic patients presenting without bowel obstruction.
In the present series, a longer diagnostic and therapeutic
delay was not associated with worse survival.
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